Spotlight on ixazomib: potential in the treatment of multiple myeloma

被引：108

作者：

Muz, Barbara ^{[1
]}

Ghazarian, Rachel Nicole ^{[1
,2
]}

Ou, Monica ^{[1
,3
]}

Luderer, Micah John ^{[1
]}

Kusdono, Hubert Daniel ^{[1
,2
]}

Azab, Abdel Kareem ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Div Canc Biol, Dept Radiat Oncol, St Louis, MO 63108 USA

[2] St Louis Univ, St Louis Coll Pharm, Dept Pharmaceut & Adm Sci, St Louis, MO 63103 USA

[3] St Louis Univ, Dept Biol, St Louis, MO 63103 USA

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2016年 / 10卷

基金：

美国国家卫生研究院;

关键词：

proteasome inhibitor; oral administration; biological mechanism; clinical trials; PROTEASOME INHIBITOR MLN9708; BONE-MARROW MICROENVIRONMENT; BORTEZOMIB; CELLS; THERAPY; DEXAMETHASONE; GLYCOPROTEIN; CARFILZOMIB; DISEASE; CONTEXT;

D O I：

10.2147/DDDT.S93602

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the first oral PI approved by US Food and Drug Administration. This review discusses the biochemical properties, mechanisms of action, preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration approval of ixazomib.

引用

页码：217 / 226

页数：10

共 38 条

[1] The role of P-glycoprotein in drug resistance in multiple myeloma [J].

Abraham, Joseph ;

Salama, Noha N. ;

Azab, Abdel Kareem .

LEUKEMIA & LYMPHOMA, 2015, 56 (01) :26-33

[2] Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].

Adams, J ;

Behnke, M ;

Chen, SW ;

Cruickshank, AA ;

Dick, LR ;

Grenier, L ;

Klunder, JM ;

Ma, YT ;

Plamondon, L ;

Stein, RL .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338

[3] Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib [J].

Ao, Lin ;

Wu, Ying ;

Kim, Donghern ;

Jang, Eun Ryoung ;

Kim, Kyunghwa ;

Lee, Do-min ;

Kim, Kyung Bo ;

Lee, Wooin .

MOLECULAR PHARMACEUTICS, 2012, 9 (08) :2197-2205

[4] Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma [J].

Arnulf, Bertrand ;

Pylypenko, Halyna ;

Groslcki, Sebastian ;

Karamanesht, Ievgenii ;

Leleu, Xavier ;

van de Velde, Helgi ;

Feng, Huaibao ;

Cakana, Andrew ;

Deraedt, William ;

Moreau, Philippe .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12) :1925-1928

[5] CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma [J].

Azab, Abdel Kareem ;

Sahin, Ilyas ;

Azab, Feda ;

Moschetta, Michele ;

Mishima, Yuji ;

Burwick, Nicholas ;

Zimmermann, Johann ;

Romagnoli, Barbara ;

Patel, Kalpana ;

Chevalier, Eric ;

Roccaro, Aldo M. ;

Ghobrial, Irene M. .

BLOOD, 2014, 124 (12) :1905-1914

[6] Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features [J].

Azab, Abdel Kareem ;

Hu, Jinsong ;

Quang, Phong ;

Azab, Feda ;

Pitsillides, Costas ;

Awwad, Rana ;

Thompson, Brian ;

Maiso, Patricia ;

Sun, Jessica D. ;

Hart, Charles P. ;

Roccaro, Aldo M. ;

Sacco, Antonio ;

Ngo, Hai T. ;

Lin, Charles P. ;

Kung, Andrew L. ;

Carrasco, Ruben D. ;

Vanderkerken, Karin ;

Ghobrial, Irene M. .

BLOOD, 2012, 119 (24) :5782-5794

[7] P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment [J].

Azab, Abdel Kareem ;

Quang, Phong ;

Azab, Feda ;

Pitsillides, Costas ;

Thompson, Brian ;

Chonghaile, Triona ;

Patton, John T. ;

Maiso, Patricia ;

Monrose, Val ;

Sacco, Antonio ;

Ngo, Hai T. ;

Flores, Ludmila M. ;

Lin, Charles P. ;

Magnani, John L. ;

Kung, Andrew L. ;

Letai, Anthony ;

Carrasco, Ruben ;

Roccaro, Aldo M. ;

Ghobrial, Irene M. .

BLOOD, 2012, 119 (06) :1468-1478

[8] RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma [J].

Azab, Abdel Kareem ;

Azab, Feda ;

Blotta, Simona ;

Pitsillides, Costas M. ;

Thompson, Brian ;

Runnels, Judith M. ;

Roccaro, Aldo M. ;

Ngo, Hai T. ;

Melhem, Molly R. ;

Sacco, Antonio ;

Jia, Xiaoying ;

Anderson, Kenneth C. ;

Lin, Charles P. ;

Rollins, Barrett J. ;

Ghobrial, Irene M. .

BLOOD, 2009, 114 (03) :619-629

[9] CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy [J].

Azab, Abdel Kareem ;

Runnels, Judith M. ;

Pitsillides, Costas ;

Moreau, Anne-Sophie ;

Azab, Feda ;

Leleu, Xavier ;

Jia, Xiaoying ;

Wright, Renee ;

Ospina, Beatriz ;

Carlson, Alicia L. ;

Alt, Clemens ;

Burwick, Nicholas ;

Roccaro, Aldo M. ;

Ngo, Hai T. ;

Farag, Mena ;

Melhem, Molly R. ;

Sacco, Antonio ;

Munshi, Nikhil C. ;

Hideshima, Teru ;

Rollins, Barrett J. ;

Anderson, Kenneth C. ;

Kung, Andrew L. ;

Lin, Charles P. ;

Ghobrial, Irene M. .

BLOOD, 2009, 113 (18) :4341-4351

[10] From Bortezomib to other Inhibitors of the Proteasome and Beyond [J].

Buac, Daniela ;

Shen, Min ;

Schmitt, Sara ;

Kona, Fathima Rani ;

Deshmukh, Rahul ;

Zhang, Zhen ;

Neslund-Dudas, Christine ;

Mitra, Bharati ;

Dou, Q. Ping .

CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (22) :4025-4038

← 1 2 3 4 →